[{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioDelivery Sciences Announces Phase I Clinical Trial Results at the American Academy of Pain Medicine\u2019s 36th Annual Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"BioDelivery Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioDeliver.."},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camurus Announces Submission of Request for Final Approval of Brixadi\u2122 for the Treatment of Opioid Use Disorder in the US","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Camurus","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camurus \/ .."},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Indegene Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Titan Pharmaceuticals And Indegene Enter Into Probuphine\u00ae Co-Promotion Partnership","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Titan Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Subdermal Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Indegene Inc","highestDevelopmentStatusID":"12","companyTruncated":"Titan Phar.."},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Molteni Farmaceutici","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Accord Healthcare Enters Exclusive Distribution Agreement with Molteni Farmaceutici for First Buprenorphine Implant Approved in Europe","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Implant","sponsorNew":"Accord healthcare \/ Molteni Farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"Accord hea.."},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA\u00ae to Oxycodone at the 2021 NANS Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioDeliver.."},{"orgOrder":0,"company":"Alar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alar Pharm.."},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Australian TGA Approves Key Label Updates to Buvidal\u00ae for Treatment of Opioid Dependence","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Camurus","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camurus \/ .."},{"orgOrder":0,"company":"Braeburn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braeburn Resubmits New Drug Application for BRIXADI","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braeburn","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braeburn \/.."},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyndra Therapeutics Presents Preclinical Data on Once-Weekly Oral Buprenorphine Treatment, LYN-013, in Development for Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lyndra Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Extended release Capsule","sponsorNew":"Lyndra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lyndra The.."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indivior to Present New Data on Opioid Use Disorder at CSAM-SMCA 2021 Scientific Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Alvogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioDelivery Sciences Prevails in BELBUCA\u00ae ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Alvogen","highestDevelopmentStatusID":"12","companyTruncated":"BioDeliver.."},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","amount":"$604.0 million","upfrontCash":"$604.0 million","newsHeadline":"Collegium Completes the Acquisition of BDSI","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0.59999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0.59999999999999998,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Collegium","highestDevelopmentStatusID":"12","companyTruncated":"BioDeliver.."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indivior Publishes Modeling Data Showing Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression in Chronic Opioid Users","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indivior Announces Seven Abstracts Accepted for Presentation at the 84th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indivior Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Xiromed","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Emplicure","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emplicure AB Announce Completion of Phase I PK Study for EMPLI03 with Quotient Sciences","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Emplicure","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emplicure \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Emplicure .."},{"orgOrder":0,"company":"Braeburn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Braeburn's New Drug Application Resubmission for BRIXADI\u2122 (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braeburn","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braeburn \/.."},{"orgOrder":0,"company":"Braeburn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braeburn Receives Complete Response Letter for the NDA for BRIXADI\u2122 (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braeburn","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Braeburn \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braeburn \/.."},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","amount":"$604.0 million","upfrontCash":"$604.0 million","newsHeadline":"Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0.59999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0.59999999999999998,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"BioDeliver.."},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Emplicure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure\u2019s First Clinical Pharmacokinetic Study for EMPLI03","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Quotient Sciences \/ Emplicure","highestDevelopmentStatusID":"6","companyTruncated":"Quotient S.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Announces Receipt of Complete Response Letter from the FDA for Xiromed-Partnered Buprenorphine Buccal Film","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Xiromed","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camurus Announces FDA Approval of Brixadi\u2122 for the Treatment of Moderate to Severe Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Camurus","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camurus \/ .."},{"orgOrder":0,"company":"Braeburn","sponsor":"Altruix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altruix Approved to Dispense Brixadi\u00ae for Moderate to Severe Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Partnership","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braeburn","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Braeburn \/ Altruix","highestDevelopmentStatusID":"12","companyTruncated":"Braeburn \/.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Indivior","sponsor":"Alar Pharmaceuticals","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Indivior \/ Alar Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Difgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DifGen Pharmaceuticals Successfully Launches A Second Product - Buprenorphine Transdermal System From Its US Manufacturing Site Aveva Drug Delivery Systems; Expanding Its Portfolio Of Manufacturing & Marketing US Made Transdermal Patches And Sublingual Fi","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Difgen","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Patch","sponsorNew":"Difgen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Difgen \/ N.."},{"orgOrder":0,"company":"Xiromed","sponsor":"IntelGenx","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Updates Status of Buprenorphine Buccal Film ANDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Xiromed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Film","sponsorNew":"Xiromed \/ IntelGenx","highestDevelopmentStatusID":"10","companyTruncated":"Xiromed \/ .."}]
Find Clinical Drug Pipeline Developments & Deals for Buprenorphine
Details :
Under the partnership, Quotient Sciences will support the GMP manufacture and first clinical pharmacokinetic (PK) study for EMPLI03 (buprenorphine) using its unique Translational Pharmaceutics® platform for the treatment of moderate to severe pain.
Details :
Belbuca-Generic (buprenorphine) is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. It is indicated to manage chronic pain severe. It has received CRL from FDA for its resubmitted ANDA.
Details :
Buprenorphine Transdermal System is a partial opioid agonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.
Details :
Under the agreement with Alar, Indivior will secure exclusive global rights (except in China, Hong Kong, Taiwan and Macau) to develop, manufacture and commercialize ALA-1000 and Alar's future buprenorphine-based LAI product candidates.
Details :
Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. It is indicated to manage chronic pain severe enough to require daily, around-the-clock, long-term treatment with an opioid.
Details :
Under the partnership, Altruix has been selected as a limited distribution partner for Brixadi (buprenorphine), an opioid medication and an extended-release subcutaneous injection indicated for the treatment of moderate to severe opioid use disorder pati...
Details :
Brixadi™ (buprenorphine) injection for SC, will be indicated for the treatment of severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with bupre...
Details :
Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. It is indicated to manage chronic pain severe enough to require daily, around-the-clock, long-term treatment with an opioid.
Details :
BRIXADI is an investigational, extended-release SC injectable therapy under review by FDA for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product.
Details :
BRIXADI, SC injection, will be indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.